Is there a difference in the efficacy of COVID-19 vaccine in males and females? - A systematic review and meta-analysis

References

• World Health Organisation Coronavirus disease (COVID-19) Situation dashboard; 2021 May 14 [accessed 2021 May 14]. https://covid19.who.int/ .
   Google Scholar
• Xu L, Mao Y, Chen G. Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis. Aging. 2020;12(12):12410–21. doi:10.18632/aging.103383.
   PubMedGoogle Scholar
• Qiao Y, Wang XM, Mannan R, Pitchiaya S, Zhang Y, Wotring JW, Xiao L, Robinson DR, Wu Y-M, Tien JC-Y, Cao X, Simko SA, Apel IJ, Bawa P, Kregel S, Narayanan SP, Raskind G, Ellison SJ, Parolia A, Zelenka-Wang S, McMurry L, Su F, Wang R, Cheng Y, Delekta AD, Mei Z, Pretto CD, Wang S, Mehra R, Sexton JZ, Chinnaiyan AM. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Proc Natl Acad Sci USA. 2020;118:e2021450118.
   Web of Science ®Google Scholar
• Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315–20. doi:10.1038/s41586-020-2700-3.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33(1):577–99. doi:10.1146/annurev-cellbio-100616-060718.
   PubMed Web of Science ®Google Scholar
• Bischof E, Oertelt-Prigione S, Morgan R, Klein S. Towards precision medicine: inclusion of sex and gender aspects in COVID-19 clinical studies-acting now before it is too late-a joint call for action. Int J Environ Res Public Health. 2020;17(10):3715. doi:10.3390/ijerph17103715.
   PubMed Web of Science ®Google Scholar
• Tannenbaum C, Ellis RP, Eyssel F, Zou J, Schiebinger L. Sex and gender analysis improves science and engineering. Nature. 2019;575(7781):137–46. doi:10.1038/s41586-019-1657-6.
   PubMed Web of Science ®Google Scholar
• Kim JH, Hotez P, Batista C, Ergonul O, Figueroa JP, Gilbert S, Gursel M, Hassanain M, Kang G, Lall B, Larson H, Naniche D, Sheahan T, Shoham S, Wilder-Smith A, Strub-Wourgaft N, Yadav P, Bottazzi ME. Operation warp speed: implications for global vaccine security. Lancet Global Health. 2021;9:e1017–e1021.
   Web of Science ®Google Scholar
• Vijayasingham L, Bischof E, Wolfe J. Sex-disaggregated data in COVID-19 vaccine trials. The Lancet. 2021;397(10278):966–67. doi:10.1016/S0140-6736(21)00384-6.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Med PGJP. 2009;6:e1000097.
   Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   Google Scholar
• Peterson J, Welch V, Losos M, Tugwell PJOOHRI The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2011.
   Google Scholar
• Higgins JP, Thompson S. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine. 2002;21(11):1539–1558.
   Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23. doi:10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403‐16. doi:10.1056/NEJMoa2035389.
   Web of Science ®Google Scholar
• COVID-19 breakthrough case investigations and reporting; 2021 May 7 [accessed 2021 April 26]. https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html .
   Google Scholar
• Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38. doi:10.1038/nri.2016.90.
   PubMed Web of Science ®Google Scholar
• Tadount F, Doyon-Plourde P, Rafferty E, MacDonald S, Sadarangani M, Quach C. Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? - A systematic review. Vaccine. 2020;38(3):444–59. doi:10.1016/j.vaccine.2019.10.091.
   PubMed Web of Science ®Google Scholar
• Chambers C, Skowronski DM, Rose C, Serres GD, Winter A-L, Dickinson JA, Jassem A, Gubbay JB, Fonseca K, Drews SJ, et al. Should sex be considered an effect modifier in the evaluation of influenza vaccine effectiveness? Open Forum Infect Dis. 2018;5(9):ofy211. doi:10.1093/ofid/ofy211.
   PubMed Web of Science ®Google Scholar
• Dhakal S, Klein Sabra L, Coyne Carolyn B. Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J Virol. 2019;93(21):e00797–19. doi:10.1128/JVI.00797-19.
   PubMed Web of Science ®Google Scholar